Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

GlaxoSmithKline PLC (NYSE:GSK)

43.14
BATS BZX Real-Time Price
As of 3:01pm ET
 -0.20 / -0.46%
Today’s Change
36.71
Today|||52-Week Range
44.85
+8.44%
Year-to-Date
European Stocks: What's Your Pain Tolerance?
10:04am / TheStreet.com - Paid Partner Content
GlaxoSmithKline (GSK) Flagged As Today's Pre-Market Laggard
Jun 27 / TheStreet.com - Paid Partner Content
Better Buy: GlaxoSmithKline plc vs. Merck
8:23am / MotleyFool.com - Paid Partner Content
Post-Brexit Analysis: Should Investors Buy or Sell Biopharma?
Jun 24 / MotleyFool.com - Paid Partner Content
'Shark Tank's' Kevin O'Leary Finds 'The Opportunity of a Lifetime'
Jun 30 / TheStreet.com - Paid Partner Content
AstraZeneca Nasal Spray Flu Vaccine To be Hit By ACIP Vote
Jun 23 / Zacks.com - Paid Partner Content
These 3 Biotechs Are Down More Than 36% This Year, and They're Bargains
Jun 29 / MotleyFool.com - Paid Partner Content
Zika vaccine maker's stock is on fire
Jun 22 / CNNMoney.com
New Stock Research Reports for June 28, 2016
Jun 28 / Zacks.com - Paid Partner Content
Can These Upstarts Knock Gilead Sciences Off Its Perch?
Jun 22 / MotleyFool.com - Paid Partner Content
Shire and Glaxo Offer Prescription to London's Woes
Jun 28 / TheStreet.com - Paid Partner Content
7 Pharmaceutical Stocks With Dividends Yielding More Than 3%
Jun 21 / MotleyFool.com - Paid Partner Content
Better Buy: NantKwest, Inc. vs. Ionis Pharmaceuticals
Jun 28 / MotleyFool.com - Paid Partner Content
New Stock Research Reports for June 21, 2016
Jun 21 / Zacks.com - Paid Partner Content
Regulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied?
Jun 27 / MotleyFool.com - Paid Partner Content
Glaxo/Innoviva's Closed Triple Combination Tops Phase III
Jun 21 / Zacks.com - Paid Partner Content
Mylan Launches Generic Version of Glaxo's Avodart in U.S.
Jun 27 / Zacks.com - Paid Partner Content
How Inovio Pharmaceuticals Is Leading the Zika Vaccine Race
Jun 21 / MotleyFool.com - Paid Partner Content
How Does Brexit Impact Healthcare Stocks?
Jun 27 / Zacks.com - Paid Partner Content
3 Reasons Gilead Sciences Is a Buy
Jun 17 / MotleyFool.com - Paid Partner Content